Beskrivning
Land | Danmark |
---|---|
Lista | First North Denmark |
Sektor | Hälsovård |
Industri | Medicinteknik |
19.12.2019 10:03:25 CET | ViroGates | Company Announcement
ViroGates A/S (Nasdaq First North Denmark: VIRO) has published its financial calendar for 2020 with the following key dates:
23 March: Deadline for submission of business to be transacted at the 2020 Annual General Meeting
25 March: Annual Report 2019
28 April: Annual General Meeting
30 April: Interim Report Q1 2020
13 August: Interim Report Q2 2020
27 October: Interim Report Q3 2020
The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after their release.
Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 23 March 2020 via email to jk@virogates.com.
For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email: jk@virogates.com
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com
About ViroGates
ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates’ suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics’ Cobas instruments and ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets. www.virogates.com